CAR-T

Blood samples in lab
#Blood cancer #CAR-T #Cell and gene therapy #Elicera Therapeutics #Phase I trial #Swedish Medical Products Agency

CAR-T therapy for B-cell lymphoma enters trials in Sweden

Cell and gene therapy company Elicera Therapeutics has received approval from the Swedish Medical Products Agency to start the clinical Phase I/II study CARMA in patients with B-cell lymphoma who no longer respond to standard treatment or have relapsed. CARMA is a single-arm, unblinded, multicentre study… Read More

#Cancer Research #News

#Bispecific Antibodies #Blood cancer #Cancer research #CAR-T #JAK inhibitor #Oncology

This week in drug discovery (29 January – 2 February) 

News round-up for 29 January – 2 February by DDW Digital Content Editor Diana Spencer. Sunday 4 February is World Cancer Day, an international awareness day led by the Union for International Cancer Control (UICC), so the round-up this week will focus on oncology, including the UK approval of… Read More

#News

CAR-T therapy
#CAR-T #Cell and gene therapy #Cell therapy #Immunotherapy #Kyverna Therapeutics #Oncology

Novel CAR T-cell vein-to-vein process could reduce time and cost

A paper in BioRxiv has described a new process that could improve the chimeric antigen receptor (CAR) T-cell patient experience and reduce costs through a minimisation of the CAR T-cell therapy vein-to-vein process. The process utilises less than 300ml of whole blood from a blood draw… Read More

#Cancer Research #News

European map
#Advanced Therapies Europe #Biologics / Biotechnology #Cancer immunotherapy #CAR-T #Cell and gene therapy #Cell therapy #Collaboration #Europe #Immuno-oncology #Market reporting #Oncology #Start-ups

New podcast: Why is Europe a drug discovery epicentre?

This is the latest episode of the free DDW narrated podcast, titled “Revolutionary technology for drug discovery and development” which covers three written for Volume 23 – Issue 4, Fall 2022 of DDW. They are called: European drug discovery and development success stories,… Read More

#News

#CAR-T #FDA #MHRA #Monoclonal antibodies #NMPA #Oncology #Regulatory

New DDW Highlights podcast: 15 January 2024

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  This week has seen a number of significant discoveries by researchers in academic institutions,… Read More

#News

#CAR-T #FDA #MHRA #Monoclonal antibodies #NMPA #Oncology #Regulatory

This week in drug discovery (8-12 January) 

News round-up for 8-12 January by DDW Digital Content Editor Diana Spencer. This week has seen a number of significant discoveries by researchers in academic institutions, in some cases in partnership with industry, emphasising the important role universities play in early-stage drug discovery. Perhaps most importantly,… Read More

#News

Cell and gene therapy
#Adverse event #Blood cancer #CAR-T #Cell and gene therapy #Cell therapy #FDA #Immunotherapy #ISCT #Oncology

Experts comment on FDA report on risk of T-cell malignancy  

The International Society for Cell & Gene Therapy (ISCT) has announced the publication in Nature Medicine of an expert consortium commentary addressing a recent statement from the US Food & Drug Administration (FDA) that it is investigating serious risk of T-cell malignancy in patients who received treatment with BCMA- or… Read More

#News #Regulatory

#CAR-T #FDA #MHRA #Monoclonal antibodies #NMPA #Oncology #Regulatory

New DDW Highlights podcast for 8 January 2024

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  The start of 2024 has seen quite a bit of regulatory activity, with the… Read More

#News

#CAR-T #FDA #MHRA #Monoclonal antibodies #NMPA #Oncology #Regulatory

This week in drug discovery (1-5 January) 

News round-up for 1-5 January by DDW Digital Content Editor Diana Spencer. The start of 2024 has seen quite a bit of regulatory activity, with the UK MHRA’s launch of a new procedure for assessing drugs, along with significant regulatory approvals for therapeutics for cytomegalovirus, melanoma,… Read More

#News

T cell attacking cancer cell
#AbbVie #CAR-T #Collaboration #Haematology #In vivo #Umoja Biopharma

Collaboration boosts development of novel in-situ CAR-T cell therapies

AbbVie and Umoja Biopharma have entered into two exclusive option and license agreements to develop multiple in-situ generated CAR-T cell therapy candidates in oncology. The first agreement provides AbbVie an exclusive option to license Umoja's CD19 directed in-situ generated CAR-T cell therapy candidates. This includes UB-VV111, Umoja's lead clinical programme… Read More

#Business & Investment #News

CAR-T therapy
#CAR-T #Cell therapy #Kyverna Therapeutics #Multiple sclerosis #Phase II trial

CAR-T therapy offers new hope to multiple sclerosis patients

Kyverna Therapeutics has revealed plans to progress to Phase II trials of KYV-101 for multiple sclerosis (MS) following a green light from the US Food and Drug Administration (FDA). KYV-101 is an autologous, fully human CD19 chimeric antigen receptor (CAR) T-cell product candidate for use in… Read More

#News

#American Society of Hematology #Blood cancer #Cancer research #CAR-T #Haematology #Oncology

New DDW Highlights podcast for 19 December 2023

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  Our news highlights this week focus on haematology, thanks in part to a number… Read More

#News

#American Society of Hematology #Blood cancer #Cancer research #CAR-T #Haematology #Oncology

This week in drug discovery (11-15 December) 

News round-up for 11-15 December by DDW Digital Content Editor Diana Spencer. Our news highlights this week focus on haematology, thanks in part to a number of key announcements at the 65th American Society for Hematology meeting (ASH) Annual Meeting, including real-world evidence on the use of… Read More

#News

Blood cancer
#Acute Myeloid Leukaemia #Biologics #Blood cancer #CAR-T #University College London #ViroCell Biologics

UCL accelerates research of relapse in childhood blood cancer 

The University College London (UCL) has entered into a partnership with ViroCell Biologics to advance Professor Persis Amrolia’s innovative chimeric antigen receptor (CAR) T-cell therapy for relapsed paediatric acute lymphoblastic leukaemia (ALL).   Dr Amrolia is Professor of Transplantation Immunology at the UCL Great Ormond Street Institute of… Read More

#Cancer Research #News

Antibodies
#Antibodies #Antibody discovery workflow #Antibody drug conjugate (ADC) #CAR-T #Therapeutic Antibodies

Fortis Life Sciences leads the way in custom antibody discovery

This article is sponsored by Fortis Life Sciences. In the ever-evolving landscape of therapeutic development, the role of antibodies has become increasingly apparent. Antibodies are used as therapeutics, components of therapeutics such as antibody-drug conjugates (ADC) and CAR-T cells, and as companion diagnostic tools. Fortis Life Sciences offers… Read More

#News

CAR-T therapy
#Blood cancer #CAR-T #Haematology #Kite Pharma #Oncology #Real world data

Real-world evidence supports use of CAR-T therapies in blood cancers

Real-world evidence from the French DESCAR-T registry has shown an overall response rate (ORR) of 76.9% and complete response rate (CR) of 57.7% in large B-cell lymphoma (LBCL) patients treated with axicabtagene ciloleucel (Yescarta). Axicabtagene ciloleucel was also associated with less than 5% grade ≥3 cytokine… Read More

#Cancer Research #News #Trending News